What does a “true strategic partnership” between sponsors and CDMOs look like in today’s environment?
🔬 As biologics expand beyond mAbs into increasingly complex modalities, from ADCs and bispecifics to gene therapies, collaboration across the value chain is now more critical than ever.
In this recent Pharma’s Almanac roundtable, industry leaders share perspectives on the evolving role of CDMO partnerships. Jongkyu Yoon, Vice President and Head of Project Management at Samsung Biologics, highlights how these partnerships are moving beyond transactional engagements toward strategic collaborations built on shared roadmaps for long-term success.
🔬 As biologics expand beyond mAbs into increasingly complex modalities, from ADCs and bispecifics to gene therapies, collaboration across the value chain is now more critical than ever.
In this recent Pharma’s Almanac roundtable, industry leaders share perspectives on the evolving role of CDMO partnerships. Jongkyu Yoon, Vice President and Head of Project Management at Samsung Biologics, highlights how these partnerships are moving beyond transactional engagements toward strategic collaborations built on shared roadmaps for long-term success.
Share article
Related Content